Finding Markers of Sudden Cardiac Death Risk After Heart Attack
Looks for risk markers of sudden cardiac death in people after a heart attack.
Plain-language title generated from the registry record
Registry title: ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY
Key facts
- Where
- Amiens, Bordeaux, Brest, Caen, Clermont-Ferrand, Lille, Lyon, Nancy, Nantes, Paris, Poitiers, Saint-Etienne, Strasbourg, Toulouse, and Vichy, FranceSee the 16 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07545512, who can take part
Where in France
- CHU AmiensAmiens, FranceNot yet recruiting
- CHU BordeauxBordeaux, FranceTaking people
- Chu BrestBrest, FranceNot yet recruiting
- CHU CaenCaen, FranceNot yet recruiting
- CHU Clermont-FerrandClermont-Ferrand, FranceNot yet recruiting
- CHRU LilleLille, FranceTaking people
- HCL - Hôpital de la Croix RousseLyon, FranceNot yet recruiting
- HCL - Hôpital Pierre WertheimerLyon, FranceNot yet recruiting
- CHU NancyNancy, FranceNot yet recruiting
- CHU Nantes - Hopital Nord LaënnecNantes, FranceTaking people
- APHP Hôpital Européen Georges PompidouParis, FranceNot yet recruiting
- CHU de PoitiersPoitiers, FranceNot yet recruiting
- CHU Saint-EtienneSaint-Etienne, FranceNot yet recruiting
- CHU StrasbourgStrasbourg, FranceTaking people
- CHU ToulouseToulouse, FranceNot yet recruiting
- CH VichyVichy, FranceNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Clermont-Ferrand
- Trial code
- NCT07545512
- Record updated
- 9 November 2026
- Original description
Although advances in treatment and patient management have considerably improved post-infarction prognosis, the risk of sudden cardiac death remains a major concern. Sudden cardiac death (SCD) is defined as an unexpected death occurring within one hour of the onset of symptoms, often of arrhythmic origin. In patients who have survived a myocardial infarction, sudden death represents a persistent threat. This risk is often associated with complications such as left ventricular dysfunction, malignant ventricular arrhythmias, and structural alterations of the myocardium, all of which can favor the development of fatal cardiac events. Among the risk factors identified, reduced left ventricular ejection fraction, a history of ventricular arrhythmias and the presence of extensive scarring of the myocardium are particularly significant.Read full original descriptionShow less
ODISSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY (ODISSEY-SCD
Although advances in treatment and patient management have considerably improved post-infarction prognosis, the risk of sudden cardiac death remains a major concern. Sudden cardiac death (SCD) is defined as an unexpected death occurring within one hour of the onset of symptoms, often of arrhythmic origin. In patients who have survived a myocardial infarction, sudden death represents a persistent threat. This risk is often associated with complications such as left ventricular dysfunction, malignant ventricular arrhythmias, and structural alterations of the myocardium, all of which can favor the development of fatal cardiac events. Among the risk factors identified, reduced left ventricular ejection fraction, a history of ventricular arrhythmias and the presence of extensive scarring of the myocardium are particularly significant.
Assessing the risk of SCD in post-infarction patients is crucial to determining appropriate prevention strategies, such as implanting automatic implantable defibrillators (ICDs). Assessment tools are varied, but currently only left ventricular ejection fraction (LVEF) < 35% is identified and validated. However, this risk stratification is unsatisfactory, particularly in view of SCD in patients with a history of myocardial infarction and a moderately impaired LVEF (between 35 and 50%). Although the initial treatment of myocardial infarction is essential for the patient's immediate survival, managing the risk of sudden death in the long term remains a major clinical challenge. A multiparametric approach is needed to optimize prognosis and prevent premature death in these patients.
Inclusion: Patients over 18 years of age; Hospitalized for acute STEMI within 6 months (Type 1 myocardial infarction according to ESC recommendations, Thygesen EHJ 2018); Left ventricular ejection fraction between 35% and 50% at least 40 days after acute myocardial infarction (see above); Under optimal tolerated medical treatment; Covered by a social security scheme; Legally competent to give voluntary informed consent to participate in the study; Patient who will not participate in further studies involving an investigational drug or device until the end of the trial (i.e. 60 months). Participation in registries is authorized.
Exclusion: Administration of ventricular antiarrhythmic drugs other than beta-blockers (i.e. amiodarone, sotalol, flecainide); Patient participating in another clinical research protocol involving an investigational drug or device within the last 30 days (participation in a registry is permitted at the same time); Patients with systemic diseases (cancer, liver failure or end-stage renal disease); Age > 80; The subject is pregnant or nursing or positive beta HCG for women of childbearing age; Presence of a secondary prevention indication for implantation of an implantable automatic defibrillator (ICD); Presence of a pacemaker; Patients with assessed life expectancy < 1 year; Adult patient under legal protection (guardianship, curatorship or other legal protection measure).